All the news Showing 10 of 30 articles from: Genotype 4Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation Liz Highleyman / 18 November 2015 A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor velpatasvir from Gilead Sciences produced sustained response in 99% of people with hepatitis C virus genotypes 1, 2, 4, 5 and 6, ... Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients Liz Highleyman / 17 November 2015 A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest phase 3 trial to ... Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes Manual Items / 02 November 2015 Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 FDA approves Technivie for treatment of chronic hepatitis C genotype 4 FDA / 27 July 2015 Sofosbuvir/ledipasvir cures more than 90% of people with hepatitis C genotypes 4 and 5 Liz Highleyman / 20 May 2015 An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study ... NICE consults on draft guidance recommending ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C NICE / 04 March 2015 Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4 Liz Highleyman / 13 November 2014 [Editor's Note: this article previously stated that the PEARL-I trial tested the AbbVie 3D Viekira Pak regimen for HCV genotype 4. In actuality, the study used the 2D regimen consisting of the paritaprevir coformulation without dasabuvir. The article has been corrected.] Sofosbuvir/ledipasvir without ribavirin and ... Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic hepatitis C genotypes 1, 2, ... Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4 Liz Highleyman / 28 May 2014 A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not as effective, according to a ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive